Friday, February 21, 2014

Oligonucleotide Therapeutics for Spinal Muscular Atrophy Impresses in Clinical Study

In addition to the continued validation of RNAi in Man, the other big winner of 2013 in the field of oligonucleotide therapeutics was single-strand phosphorothioate chemistry in the CNS.  Today, ISIS Pharmaceuticals announced clinical data from the most prominent candidate in that effort, namely ISIS-SMNRx for spinal muscular atrophy (SMA), a genetic muscle-wasting disease.  Following intrathecal administration of the splice modulating oligonucleotide, time- and dose-dependent improvements were observed not only in muscle function, but also in SMN protein production (biomarker), thus laying the foundation for an accelerated approval pathway.

In the open-label phase Ib/IIa study in ~30 children with the ‘less severe’ form of type II and III SMA, functional improvements of 1.5, 2.3, and 3.7 points on the HFMSE scale were seen at the 3mg (3 doses), 6mg (3 doses), and 9mg (2 doses) cohorts, respectively.  The changes were thus largely consistent with results from a previous similar, but single-dose phase I study where a 3.1 point increase could be observed at the 9mg dose.

Despite the generally positive news, the data raise a number of questions.  For example, optimal dosing frequency remains uncertain as there were similar functional improvements regardless of whether a single dose had been given or 2-3 doses.  This could have been due to the  long half-life of the drug and the time it takes from SMN protein production (as a  result of the splice modulation) to impacting motor neuron function.  Similarly, in the prior phase I study no positive changes in HFMSE scores were observed at the 3mg and 6mg doses whereas in the present study, improvements were reported.  Clearly, larger patient numbers are required  to settle on the optimal dose, and in fact this dose may not have been reached yet (note: a 12mg cohort has been initiated and children from the phase Ib/IIa trial are allowed to roll over to an additional dose of 12mg).

Case for accelerated approval?

Possibly foreseeing such issues due to small patient numbers, ISIS Pharmaceuticals and BiogenIdec recently developed an assay that allows them to measure SMN protein abundance in the cerebral spinal fluid (CSF).  It is the results from these measurements that provide a strong case for why ISIS-SMNRx should be made available (pending the 12mg results) before a larger phase III study will have been completed.  This is because the functional improvements were accompanied by increases in the SMN protein which also were dose-dependent with a more than doubling of SMN protein at 9mg.

In SMA, the SMN1 protein is missing due to mutations.  The therapeutic approach of ISIS-SMNRx takes advantage of the fact that humans have a pretty much identical gene to SMN1, SMN2.  The problem with SMN2, however, is that only ~10% of its precursor messenger RNAs is spliced into a functional SMN protein due to a difference in essentially just one nucleotide in exon 7.  The severity of the disease, i.e. whether somebody belongs to type I (most severe), type II, type III, or type IV of the disease depends on the copy number of SMN2 genes: 2 copies in type I, ~3 copies in type II and III, and at least 4 copies in type IV.

Therefore, doubling the protein output for type II and III patients (the patient population in the present phase Ib/IIa study) would appear to put the children into the type IV category in terms of protein output (correponding to ~6 SMN2 copies).  In contrast to type I-III, type IV results in no differences in life-expectancy and only in rare cases causes patients to be wheelchair-bound late in life.  

Severe disease of high unmet need, strong biomarker data with highly suggestive functional results, all dose-proportional…the ingredients for an accelerated approval. 



Just in: ISISis reporting preliminary data from a parallel multi-dose phase II study in the most severe, infant form of SMA (type I).  Although small in numbers, the fact that the 4 babies at the starting 6mg dose are still alive and without permanent respiratory support at an average age of 12.5 months appears to be much better than expected.  According to natural history data, you would have expected 2 babies either dead or on permanent ventilation by month 10.  

And finally...the ISIS-SMNRx results increase the value of Marina Biotech's CRN chemistry.  This chemistry competes with the ISIS 2'MOE chemistry employed in ISIS-SMNRx and appears to be of higher potency/affinity, but much less defined safety.

12 comments:

Eric said...

ISIS SMN-Rx is a 2'-MOE modified oligo. Marina's CRN modification is not similar to 2'-MOE, but rather similar to ISIS's generation 2.5 chemistry or Santaris' LNA chemistry. Why would you make the comparison in the last paragraph? Perhaps you are invested in Marina and want some of the glow of today's results to rub off on Marina? Don't get me wrong, I think the CRN chemistry is interesting and potentially valuable, but the comparison you made does not seem to make sense.

Dirk Haussecker said...

Exactly, CRN probably more potent than 2'MOE SMNRx.

And yes, as I have said a hundred times on Twitter, probably here on this blog, and other venues, I hold shares in Marina Biotech. I don't have an issue of pointing out the obvious if it helps making the markets more efficient and helps my investments. Do you?

Eric said...

Dirk there is nothing "obvious" about science unless you are in the IP field. Until CRN is proven in the clinic it is not obvious that it is better than the 2'MOE modification. I agree it has potential and look forward to seeing it proven in more rigorous testing.

Anonymous said...

See slide 29 of Isis' JP Morgan presentation last month. In the Phase I, the 6 mg cohort showed a 2.5 point improvement in HFSME score after 14 months. So Phase I 6mg cohort results consistent with Phase II 6 mg cohort results.

Dirk Haussecker said...

Well, for CRN there is at least pre-clinical data, and taken into account of what we know about 2'MOE, LNA, cETs, I think it is fair to extrapolate.

PS: don't understand your comment about understanding science and IP. Are you saying patent attorneys are better suited at evaluating oligo science than a scientist? OK...

Eric said...

No Dirk, quite the opposite. I am saying the term "obvious" is used in patent speak and I find it ridiculous. I am saying that even if a scientist thinks something should be true based on extrapolation, if he/she is good, they will realize they still need to prove it. Unlike in the patent world where inventions can be rejected due to "obviousness rejections"

Dirk Haussecker said...

OK, I get it now. Don't confuse an investment in MRNA with a claim that its CRN technology will definitely prove to be superior to ISIS chemistry. ISIS chemistry is clearly more validated in practical terms whereas the potential of CRNs needs to be figured out and realized when Marina has the capital to do so aggressively.

So the question becomes (in simplistic terms) whether the 200x differences in market caps between MRNA and ISIS can be explained by the increased technical uncertainty. I think not and keep in mind, there is a good chance it might even turn out to be superior.

Anonymous said...

If market caps. is the question. Isn't Rxi the answer?
Got put on to NASDAQ main board the other day while carrying a valuation of just tens of millions. Seems to be a move in anticipation of something.
Similarly with RGLS.

Dirk Haussecker said...

2-3 years ago when RNAi was down in the gutters, the incoming/current CEO was proud to say that he is 'NOT an oligoRx' person, but a 'small molecule person'.

Not only was this outrageous as this was ridicule of the RNAi Rx approach from a person supposed to lead such a company, but betrayed an arrogance that I can't believe allows for sound decision making. Plus add the fact that RXi has its origins in promo biotechs Galena and CytRx.

Anonymous said...

Dirk, do you think American, unlike the Swiss, parsimony in RNAi leadership will be broken by Pfizer buying out ISIS in order to get their stake in RGLS? Simultaneously, they would become a partner of ALNY.
Makes sense after the recent MRK mea culpa.
The message would be, this (antisense) is the best, forget about the rest.

Dirk Haussecker said...

I do not wish on my biggest enemies involved in innovative drug development to be take over by Pfizer.

Anonymous said...

Whilst you bask in your post-TIDES glow of recommendations for business in RNAi, how about stating what it is you would wish to see happen for your biggest friends and enemies in the sector.

By Dirk Haussecker. All rights reserved.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.